

## ESPI current report

Number: 39/2025  
 Date of preparation: September 15, 2025  
 Company: Genomtec SA based in Wrocław

Title	Receiving a decision from the Patent Office in Japan to grant patent protection
-------	---

**Legal basis:** Article 17, paragraph 1 of MAR – confidential information

**Content of the Report:** The Management Board of Genomtec S.A. with its registered office in Wrocław (hereinafter referred to as the "Issuer", "Company") hereby announces that it has received information today about a positive decision of the Patent Office in Japan granting the Company patent protection for the invention "Primer sets for the detection of human papillomavirus type 16 (HPV16) and human papillomavirus type 18 (HPV18), the method of detecting HPV16 and HPV18 infections, the use of a primer set for the detection of HPV16 and HPV18 infections", used to detect HPV16 and HPV18 viruses.

HPV16 and HPV18 are sexually transmitted viruses belonging to the human papillomavirus family. Due to their oncogenic properties, they are one of the main causes of cervical cancer development. Early diagnosis of HPV infection allows for the rapid initiation of appropriate therapeutic and diagnostic procedures and further monitoring of the patient to reduce the risk of cancer development, or for rapid diagnosis and further treatment.

The protection period for the invention in question in Japan starts on September 8, 2020 and will last until October 8, 2040, provided that the official fees for the subsequent years of protection are paid on time.

The Issuer announces that this is the third patent granted by the Japanese Patent Office and the fifteenth patent received by the Company. The Issuer has over thirty patent applications pending worldwide.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial agreements with selected partners regarding the implementation of the commercialization strategy.

Patent proceedings are aimed at securing key interests and are consistent with the Issuer's development strategy, which includes building a portfolio of intellectual property rights.